Posts Tagged ‘cell-mediated immunity’

T cell-mediated immune responses & signaling pathways activated by Toll-like Receptors

Posted in Cell Biology, Signaling & Cell Circuits, Clinical & Translational, Curation, Disease Biology, Small Molecules in Development of Therapeutic Drugs, Gene Regulation, Human Immune System in Health and in Disease, tagged cell-mediated immunity, Toll-like receptor on September 7, 2015| Leave a Comment »

T cell-mediated immune responses & signaling pathways activated by Toll-like Receptors

Curator: Larry H. Bernstein, MD, FCAP

 

 

Series E. 2; 6.10

Bruce A. Beutler, Jules A. Hoffmann, Ralph M. Steinman

Bruce Beutler, MD

Regental Professor; Raymond and Ellen Willie Distinguished Chair in Cancer Research, in Honor of Laverne and Raymond Willie, Sr.

Department Center for Genetics of Host Defense, Immunology

Bruce Beutler, MD, the son of the “father of red cell metabolic pathways”, Ernest Beutler, was born in Chicago and grew up in Los Angeles, where Beutler did his groundbreaking work on hemolytic red cell disorders at City of Hope Hospital. He was infected with an interest in medicine and research at an early age, somewhat analagous to a comparison with Roger and Arthur Kornberg. He attended University of California San Diego (UCSD) Medical School,  where his interest in immunity was sparked by Abraham Braude, PhD, Professor Pathology and Medicine, and Chief of Microbiology.

Bruce Beutler, MD, discovered an important family of receptors that allow mammals to sense infections when they occur, triggering a powerful inflammatory response. For this work he received the 2011 Nobel Prize in Physiology or Medicine.

The period from 1950 to 1953 was critical to Abraham Braude’s career. During these years, Braude realized the importance of the microbiology laboratory not only in patient management, but also in physician education. He became convinced that infectious disease clinicians must not only be excellent microbiologists, but also exercise technical and administrative control of the diagnostic microbiology laboratory. He demonstrated and taught this principle of medical practice and education for the next 35 years as director of diagnostic microbiology and chief of infectious diseases at the Texas Southwestern Medical School  of the University of Texas from 1953-57, at the University of Pittsburgh from 1957 to 1969, and at the University of California at San Diego from 1967 until his death in December, 1984. He also was my mentor as a resident in 1972, and it was remarkable how he had developed his own antibiotic diffusion plates for sensitivity studies on bacterial isolates.

He discovered that the endotoxin of cold-growing bacteria that had contaminated refrigerated blood could cause vascular collapse and death of transfused people without bacterial multiplication in the body. This observation established the importance of endotoxin as the major virulence factor of Gram negative bacteria and set the stage for his later fundamental and applied research on the pathogenesis and treatment of life-threatening septic shock. This aspect of infection, in the host defense, is perhaps important in the development of the young Beutler.

During his years in Dallas, Pittsburgh, and San Diego, Braude made outstanding research contributions in three areas, anaerobic infections, pyelonephritis, and the endotoxin shock of Gram negative bacteremia. He devised a simple, effective method for culturing fastidious anaerobes, discovered Bacteroides penicillinase, and proved that so-called “sterile” brain abscesses are caused by anaerobes. His landmark papers on brain infections and sinusitis awakened us to the major role of anaerobes in infectious disease. His work on pyelonephritis ranged from devising realistic models of infection to elegant studies that helped explain the inadequacies of the immune responses of the kidney.

Beutler received his undergraduate degree from the University of California at San Diego in 1976, and his MD degree from the University of Chicago in 1981. After two years of residency at the University of Texas Southwestern Medical Center, he became a postdoctoral fellow and then an Assistant Professor at the Rockefeller University (1983-1986), where he isolated mouse tumor necrosis factor (TNF), and was the first to recognize TNF as a key executor of the inflammatory response. Returning to Dallas in 1986 as an HHMI investigator, he designed recombinant inhibitors of TNF that are widely used in the treatment of rheumatoid arthritis and other inflammatory diseases. He also used TNF as a biological endpoint in order to identify the receptor for bacterial lipopolysaccharide (LPS). This he achieved by positionally cloning the Lps mutation of mice, known to prevent all biological responses to LPS, including TNF production. He thus concluded that Toll-like receptor 4 (TLR4) acts as the signaling core of the LPS receptor and proposed that other TLRs might also recognize conserved molecular signatures of infection.

Moving in 2000 to the Scripps Research Institute, Beutler developed the largest mouse mutagenesis program in the world, and applied a forward genetic approach to decipher the signaling pathways activated by TLRs. He also identified many other molecules with non-redundant function in the immune response.

Beutler is currently a Regental Professor and Director of the Center for Genetics of Host Defense at the University of Texas Southwestern Medical Center. He also holds the Raymond and Ellen Willie Distinguished Chair in Cancer Research in honor of Laverne and Raymond Willie, Sr. He has authored or co-authored more than 300 papers, which have been cited more than 46,000 times. Before he received the Nobel Prize, his work was recognized by the Shaw Prize (2011), the Albany Medical Center Prize in Medicine and Biomedical Research (2009), election to the National Academy of Sciences and Institute of Medicine (2008), the Frederik B. Bang Award (2008), the Balzan Prize (2007), the Gran Prix Charles-Leopold-Mayer (2006), the William B. Coley Award (2005), the Robert-Koch-Prize (2004), and other honors.

“Monitored Saturation Mutagenesis of the Mouse Genome”

Bruce Beutler, University of Texas Southwestern Medical Center, TX USA

The availability of massively parallel sequencing platforms has accelerated the identification of induced mutations in the mouse genome. However, genetic mapping has remained essential to identify causative mutations, and for a time, became the rate-limiting step in mammalian forward genetics. We have recently described a procedure that permits real time identification of mutations responsible for phenotypes of any kind. By inducing mutations on a defined genetic background (C57BL/6J) and sequencing the whole exome of all G1 carriers of these mutations, we are able to identify all candidate aberrations that might cause phenotype in descendants of the G1. We then genotype all G3 mice to determine zygosity at each mutation site. Pre-genotyped G3 mice are distributed for extensive phenotypic screening. As quantitative phenotypic data are uploaded to the computer, an automated search for correlation between phenotype and genotype is initiated using dominant, recessive and semidominant models of transmission. The computer returns a list of statistical associations between specific mutations and phenotype, allowing immediate inference regarding causation. As allelic series develop at most loci, the strength of inference increases. CRISPR/Cas9 targeting is used to validate candidates identified by automated mapping. Presently, more than 65,000 point mutations disrupting the mouse coding region have been tested in this manner. To our best estimate, 18 percent of all mouse genes have been mutated to phenovariance and examined in 135 phenotypic screens. About 50,000 mutations can be surveyed annually. A list of robust associations between mouse genes and phenotypic anomalies will facilitate genetic investigations in humans, where a uniform genetic background is not available and a heavy mutation load confounds such analysis.

 

Nobel Laureate Bruce Beutler, Guest Lecturer at the First Annual …

http://www.youtube.com/watch%3Fv%3D31rWtdpmjME  
Dec 9, 2014 … Professor Bruce Beutler, a 2011 recipient of the Nobel Prize in Medicine, was the Keynote speaker. Professor Beutler discovered the …

 

In the last few years of his life, Dr. Ralph Steinman made himself into an extraordinary human lab experiment, testing a series of unproven therapies – including some he helped to create – as he waged a very personal battle with pancreatic cancer.

The winner of the 2011 Nobel prize in medicine died only three days before the award was announced.

Immunologist Ralph Steinman was honored today by the Nobel Committee for his discovery of dendritic cells, a class of immune cells that help rally the body’s natural defenses to fight disease. However, the prize is bittersweet for all who knew the 68-year-old scientist during his long career as a researcher and mentor at Rockefeller University in New York City.

“Dendritic cells are the guys who are training the fighters,” says Pawel Kalinski, an immunologist at the University of Pittsburgh in Pennsylvania, about their role in activating T cells, the body’s immune sentries. Over decades, with Steinman often leading the way, the work transformed cancer research. Cancer vaccines either using or targeting dendritic cells are now the subject of numerous clinical trials, and the first-ever cancer vaccine to be approved in the United States—called Provenge, to treat prostate cancer—injects a patients’ own dendritic cells back into their body. It went on the market last year.

“He felt that human clinical investigation was the highest form of research, that it was critical to engage in it,” Dr. Sarah Schlesinger, Steinman’s clinical lab director and colleague at New York’s Rockefeller University, told Reuters. “He had great criticism of how slowly the process moved … he was impatient with data and mice,” she added.

 

Steinman spent his entire career on immunology research for which he won the Nobel Prize, an honor he shares with American Bruce Beutler and French biologist Jules Hoffmann for their contributions to explaining the immune system.

Steinman’s discovery of dendritic cells in 1973 led to the first therapeutic cancer vaccine, Dendreon’s Provenge, which treats men with advanced prostate cancer.

 

Jules A. Hoffmann (born 2 August 1941) is a Luxembourg-born French^[1] biologist. During his youth, growing up in Luxembourg, he developed a strong interest in insects under the influence of his father, Jos Hoffmann. This eventually resulted in the younger Hoffmann’s dedication to the field of biology using insects as model organisms.^[2] He currently holds a faculty position at the University of Strasbourg.^[3] He is a research director and member of the board of administrators of the National Center of Scientific Research (CNRS) in Strasbourg, France. He was elected to the positions of Vice-President (2005-2006) and President (2007-2008) of the French Academy of Sciences.^[3] Hoffmann and Bruce Beutler were jointly awarded a half share of the 2011 Nobel Prize in Physiology or Medicine for “their discoveries concerning the activation of innate immunity,”.^[4] [More specifically,the work showing increased Drosomycin expression following activation of Toll pathway in microbial infection.]

Hoffmann and Lemaitre discovered the function of the fruit fly Toll gene in innate immunity. Its mammalian homologs, the Toll-like receptors, were discovered by Beutler. Toll-like receptors identify constituents of other organisms like fungi and bacteria, and trigger an immune response, explaining, for example, how septic shock can be triggered by bacterial remains.^[5][6][7]

 

During his Ph.D. program under Pierre Joly, Hoffmann started his research in studying antimicrobial defenses in grasshoppers, inspired by the previous works done in the laboratory of Pierre Joly showing that no opportunistic infections were apparent in insects after the transplantation of certain organs from one to another.^[2] Hoffmann confirmed discovery of phagocytosis done by Eli Metchnikoff, through injection of Bacillus thuringiensis and observation of increase of phagocytes.^[2] In addition, he showed strong correlation between hematopoiesis and antimicrobial defenses by assessing the susceptibility of an insect to the microbial infection after X-ray treatment.^[2] Hoffmann shifts from using grasshopper model to using dipteran species in the 80s. By using Phormia terranovae, Hoffmann and his colleagues were able to identify 82-residues long antimicrobial polypeptide named Diptericin which was glycine-rich, along with other polypeptides in Drosophila melanogaster such as defensin, cecropin, and attacin.^[2] Further molecular genetic analysis revealed that the promoters for the genes encoding these antimicrobial peptides contained DNA sequences similar to the binding elements for NF-κB in mammalian DNA. Dorsal gene, critical in dorso-ventral patterning in the early embryo of Drosophila melanogaster was also identified to be in this NF-κB family. It was initially speculated by Hoffmann and colleagues that activity of Dorsal was directly linked to the expression of the Diptericin gene. However, it turned out that Diptericin was normally induced even in the loss-of-function Dorsal mutants. Further conducted research showed that Diptericin expression was dependent on the expression of imd gene. Identification of another antifungal peptide named Drosomycin and RNA blots demonstrated that two distinct pathways(Toll, Imd) exist, involving Drosomycin and Diptericin respectively. Similarities of structure and function between several members in the Drosophila embryo and members in mammals being noted, study “The Dorsoventral Regulatory Gene Cassette spảtzle/Toll/cactus Controls the Potent Antifungal Response in Drosophila Adults”^[8] by Lemaitre and Hoffmann in 1996 illuminated the possible existing innate immunity in Drosophila in response to fungal challenge. Later works identified that Toll transmembrane receptors are present in a wide variety of phyla and are conserved through evolution along with conservation of NF-κB activating cascades.^[2]

Hoffmann was a research assistant at CNRS from 1964 to 1968, and became a research associate in 1969. Since 1974 he has been a Research Director of CNRS. Between 1978 and 2005 he was Director of the CNRS research unit “Immune Response and Development in Insects”, and from 1994 to 2005 he was director of the Institute of Molecular and Cellular Biology of CNRS in Strasbourg.

 

The History of Toll-like receptors — Redefining Innate Immunity

• Luke A. J. O’Neill, Douglas Golenbock & Andrew G. Bowie

Nature Reviews Immunology13,453–460(2013)  http://dx.doi.org:/10.1038/nri3446

The discovery of Toll-like receptors (TLRs) was an important event for immunology research and was recognized as such with the awarding of the 2011 Nobel Prize in Physiology or Medicine to Jules Hoffmann and Bruce Beutler, who, together with Ralph Steinman, the third winner of the 2011 Nobel Prize and the person who discovered the dendritic cell, were pioneers in the field of innate immunity. TLRs have a central role in immunity — in this Timeline article, we describe the landmark findings that gave rise to this important field of research.

Toll–like receptor signalling : Article : Nature Reviews Immunology

http://www.nature.com/articles/nri1391

Toll–like receptors in innate immunity – International Immunology

http://intimm.oxfordjournals.org/content/17/1/1

Toll–like Receptors and Their Crosstalk with Other Innate Receptors …

http://www.sciencedirect.com/science/article/pii/S1074761311001907

 

Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity

Taro Kawai & Shizuo Akira
Immunity  27 May 2011;   34(5): 637–650,  http://dx.doi.org/10.1016/j.immuni.2011.05.006
http://www.cell.com/immunity/abstract/S1074-7613(11)00190-7

oll-like receptors (TLRs) are germline-encoded pattern recognition receptors (PRRs) that play a central role in host cell recognition and responses to microbial pathogens. TLR-mediated recognition of components derived from a wide range of pathogens and their role in the subsequent initiation of innate immune responses is widely accepted; however, the recent discovery of non-TLR PRRs, such as C-type lectin receptors, NOD-like receptors, and RIG-I-like receptors, suggests that many aspects of innate immunity are more sophisticated and complex. In this review, we will focus on the role played by TLRs in mounting protective immune responses against infection and their crosstalk with other PRRs with respect to pathogen recognition.

Invivogen – Review

Toll-Like Receptors (TLRs) play a critical role in the early innate immune response to invading pathogens by sensing microorganism and are involved in sensing endogenous danger signals.

TLRs are evolutionarily conserved receptors are homologues of the Drosophila Toll protein, discovered to be important for defense against microbial infection [1]. TLRs recognize highly conserved structural motifs known as pathogen-associated microbial patterns (PAMPs), which are exclusively expressed by microbial pathogens,
or danger-associated molecular patterns (DAMPs) that are endogenous molecules released from necrotic or dying cells.

PAMPs include various bacterial cell wall components such as lipopolysaccharide (LPS),peptidoglycan (PGN) and lipopeptides, as well as flagellin, bacterial DNA and viral double-stranded RNA. DAMPs include intracellular proteins such as heat shock proteins as well as protein fragments from the extracellular matrix.

Stimulation of TLRs by the corresponding PAMPs or DAMPs initiates signaling cascades leading to the activation of transcription factors, such as AP-1, NF-κB and interferon regulatory factors (IRFs). Signaling by TLRs result in a variety of cellular responses including the production of interferons (IFNs), pro-inflammatory cytokines and effector cytokines that direct the adaptive immune response.

 

The TLR Family

TLRs are type I transmembrane proteins characterized by an extracellular domain containing leucine-rich repeats (LRRs) and a cytoplasmic tail that contains a conserved region called the Toll/IL-1 receptor (TIR) domain.  The structure of the extracellular domain of TLR3 was revealed by crystallography studies as a large horseshoe-shape [2].
TLRs are predominantly expressed in tissues involved in immune function, such as spleen and peripheral blood leukocytes, as well as those exposed to the external environment such as lung and the gastrointestinal tract.
Their expression profiles vary among tissues and cell types. TLRs are located on the plasma membrane with the exception of TLR3, TLR7, TLR9 which are localized in the endosomal compartment [3].

Ten human and twelve murine TLRs have been characterized, TLR1 to TLR10 in humans, and TLR1 toTLR9, TLR11, TLR12 and TLR13 in mice, the homolog of TLR10 being a pseudogene.

TLR2 is essential for the recognition of a variety of PAMPs from Gram-positive bacteria, including bacterial lipoproteins, lipomannans and lipoteichoic acids. TLR3 is implicated in virus-derived double-stranded RNA. TLR4 is predominantly activated by lipopolysaccharide. TLR5 detectsbacterial flagellin and TLR9 is required for response to unmethylated CpG DNA. Finally, TLR7 andTLR8 recognize small synthetic antiviral molecules [4], and single-stranded RNA was reported to be their natural ligand [5]. TLR11(12) has been reported to recognize uropathogenic E.coli [6] and a profilin-like protein from Toxoplasma gondii [7].

The repertoire of specificities of the TLRs is apparently extended by the ability of TLRs to heterodimerize with one another. For example, dimers of TLR2 and TLR6 are required for responses to diacylated lipoproteins while TLR2 and TLR1 interact to recognize triacylated lipoproteins [8]. Specificities of the TLRs are also influenced by various adapter and accessory molecules, such as MD-2 and CD14 that form a complex with TLR4 in response to LPS [9].

 

TLR Signaling

TLR signaling consists of at least two distinct pathways: a MyD88-dependent pathway that leads to the production of inflammatory cytokines, and a MyD88-independent pathway associated with the stimulation of IFN-β and the maturation of dendritic cells.

The MyD88-dependent pathway is common to all TLRs, except TLR3 [10]. Upon activation byPAMPs or DAMPs, TLRs hetero- or homodimerize inducing the recruitment of adaptor proteins via the cytoplasmic TIR domain.
Adaptor proteins include the TIR-domain containing proteins, MyD88, TIRAP (TIR-associated protein), Mal (MyD88 adaptor-like protein), TRIF (TIR domain-containing adaptor protein-inducing IFN-β) and TRAM (TRIF-related adaptor molecule).
Recruitment of MyD88 for instance, in turn recruits IRAK1 and IRAK4. IRAK4 subsequently activates IRAK1 by phosphorylation. Both IRAK1 and IRAK4 leave the MyD88-TLR complex and associate temporarily with TRAF6 leading to its ubiquitination. Bcl10 and MALT1 form oligomers that bind to TRAF6 promoting TRAF6 self-ubiquitination [11].
Recently, IRAK2 was shown to play a central role in TRAF6 ubiquitination [12]. Following ubiquitination, TRAF6 forms a complex with TAB2/TAB3/TAK1 inducing TAK1 activation [13]. TAK1 then couples to the IKK complex, which includes the scaffold protein NEMO, leading to the phosphorylation of IκB and the subsequent nuclear localization of NF-κB. Activation of NF-κB triggers the the production of pro-inflammatory cytokines such as TNF-α, IL-1 and IL-12.

Individual TLRs induce different signaling reponses by usage of the different adaptor molecules.
TLR4 and TLR2 signaling requires the adaptor TIRAP/Mal, which is involved in the MyD88-dependent pathway [14]. TLR3 triggers the production of IFN-β in response to double-stranded RNA, in a MyD88-independent manner, through the adaptor TRIF/TICAM-1 [15]. TRAM/TICAM-2 is another adaptor molecule involved in the MyD88-independent pathway [5] which function is restricted to the TLR4 pathway [16].

TLR3, TLR7, TLR8 and TLR9 recognize viral nucleic acids and induce type I IFNs. The signaling mechanisms leading to the induction of type I IFNs differ depending on the TLR activated. They involve the interferon regulatory
factors, IRFs, a family of transcription factors known to play a critical role in antiviral defense, cell growth and immune regulation. Three IRFs (IRF3, IRF5 and IRF7) function as direct transducers of virus-mediated TLR signaling. TLR3 and TLR4 activate IRF3 and IRF7 [17], while TLR7 and TLR8 activate IRF5 and IRF7 [18]. Furthermore, type I IFN production stimulated by TLR9 ligand CpG-A has been shown to be mediated by PI(3)K and mTOR [19].

 

TLR-Targeted Therapeutics

Significant progress has been made over the past years in the understanding of TLR function [20]. TLRs are essential receptors in host defense against pathogens by activating the innate immune system, a prerequisite to the induction of adaptive immune responses.

Although TLR-mediated signaling is paramount in eradicating microbial infections and promoting tissue repair, the regulation must be tight. TLRs are implicated in a number of inflammatory and immune disorders and play a role in cancer [21].
Many single nucleotide polymorphisms have been identified in various TLR genes and are associated with particular diseases. Several therapeutic agents targeting the TLRs are now under pre-clinical and clinical
evaluation [22].

However, the complexity lies in that TLRs act as double-edged swords either promoting or inhibiting disease progression. Furthermore, therapeutic agents targeting the TLRs must be able to antagonize the harmful effects resulting without affecting host defense functions.
Nonetheless, the potential of harnessing and directing the innate immune system with drugs targeting TLRs, to prevent or treat human inflammatory and autoimmune diseases as well as cancer, appears to be promising.

 

TLR	Immune Cell Expression	PAMPs	DAMPs	Signal Adaptor	Production
TLR1+ TLR2	Cell surface Mo, MΦ, DC, B	Triacylated lipoproteins (Pam3CSK4) Peptidoglycans,Lipopolysaccharides	(TLR2 DAMPs listed below)	TIRAP, MyD88, Mal	IC
TLR2+ TLR6	Cell surface Mo, MΦ, MC, B	Diacylated lipoproteins (FSL-1)	Heat Shock Proteins (HSP 60, 70, Gp96) High mobility group proteins (HMGB1) Proteoglycans (Versican, Hyaluronic Acid fragments)	TIRAP, MyD88, Mal	IC
TLR3	Endosomes B, T, NK, DC	dsRNA (poly (I:C)) tRNA, siRNA	mRNA tRNA	TRIF	IC, type1 IFN
TLR4	Cell surface/ endosomes Mo, MΦ, DC, MC, IE	Lipopolysaccharides (LPS) Paclitaxel	Heat Shock Proteins (HSP22, 60, 70,72, Gp96) High mobility group proteins (HMGB1) Proteoglycans (Versican, Heparin sulfate, Hyaluronic Acid fragments) Fibronectin, Tenascin-C	TRAM, TRIF TIRAP, MyD88 Mal	IC, type1 IFN
TLR5	Cell surface Mo, MΦ, DC, IE	Flagellin		MyD88	IC
TLR7	Endosomes Mo, MΦ, DC. B	ssRNA Imidazoquinolines (R848) Guanosine analogs (Loxoribine)	ssRNA	MyD88	IC, type1 IFN
TLR8	Endosomes Mo, MΦ, DC, MC	ssRNA, Imidazoquinolines (R848)	ssRNA	MyD88	IC, type1 IFN
TLR9	Endosomes Mo, MΦ, DC, B,T	CpG DNA CpG ODNs	Chromatin IgG complex	MyD88	IC, type1 IFN
TLR10	Endosomes Mo, MΦ, DC	profilin-like proteins		MyD88	IC

Mo: monocytes, MΦ: marcophages, DC: dendritic cells, MC: Mast cells, B: B cells, T: T cells, IE: Intestinal epithelium, IC: Inflammatory cytokines

 

 

1. Medzhitov R. et al., 1997. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature, 388(6640):394-7.
2. Choe J. et al., 2005. Crystal structure of human Toll-like receptor 3 (TLR3) ectodomain. Science 309; 581-585.
3. Nishiya T. & DeFranco AL., 2004. Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling proper ties of the Toll-like receptors. J Biol Chem. 279(18):19008-17.
4. Jurk M. et al., 2002. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol, 3(6):499.
5. Heil F. et al., 2004. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 303(5663):1526-9.
6. Zhang D. et al., 2004. A toll-like receptor that prevents infection by uropathogenic bacteria. Science. 303:1522-1526.
7. Lauw FN. et al., 2005. Of mice and man: TLR11 (finally) finds profilin. Trends Immunol. 26(10):509-11.
8. Ozinsky A. et al., 2000.The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. PNAS USA, 97(25):13766-71.
9. Miyake K., 2003. Innate recognition of lipopolysaccharide by CD14 and toll-like receptor 4-MD-2: unique roles for MD-2. Int Immunopharmacol. 3(1):119-28.
10. Adachi O. et al., 1998. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity. 9(1):143-50.
11. Sun L. et al., 2004. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell. 2004 14(3):289-301.
12. Keating SE. et al., 2007. IRAK-2 participates in multiple Toll-like receptor signaling pathways to NFκB via activation of TRAF6 ubiquitination. J Biol Chem. 282: 33435-33443.
13. Kanayama A. et al., 2004. TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol Cell. 15(4):535-48.
14. Horng T. et al., 2002.The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature. 420(6913):329- 33.
15. Yamamoto M. et al., 2002. Cutting edge: a novel Toll/IL-1 receptor domain-containing adaptor that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol. 169(12):6668-72.
16. Yamamoto M. et al., 2003. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol. 4(11):1144-50.
17. Doyle S. et al., 2002. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity. 17(3):251-63.
18. Schoenemeyer A. et al., 2005. The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J Biol Chem. 280(17):17005-12.
19. Costa-Mattioli M. & Sonenberg N. 2008. RAPping production of type I interferon in pDCs through mTOR. Nature Immunol. 9: 1097-1099.
20. Kawai T. & Akira S., 2011. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity Immunity 34(5):637-50.
21. Rakoff-Nahoum S. & Medzhitov R., 2009. Toll-like receptors and cancer. Nat Revs Cancer 9:57- 63.
22. Hennessy E. et al., 2010. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 9(4) 293-307.

 

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on LinkedIn (Opens in new window)
• Click to share on Facebook (Opens in new window)
• Click to print (Opens in new window)
• Click to email this to a friend (Opens in new window)

Like this:

Like Loading...

Read Full Post »

• Follow Blog via Email

  Enter your email address to follow this blog and receive notifications of new posts by email.

  Join 1,979 other subscribers

  Email Address

  Follow

• Recent Posts

  • Omecamtiv mecarbil – A study examined efficacy and tolerability in Heart Failure patients with SBP ≤100 mmHg enrolled in GALACTIC-HF May 23, 2022
  • Sperm epigenetic clock and pregnancy outcomes May 14, 2022
  • Lessons on the Frontier of Gene & Cell Therapy – The Disruptive Dozen 12 #GCT Breakthroughs that are revolutionizing Healthcare May 9, 2022
  • Relevance of Twitter.com forthcoming Payment System for Scientific Content Promotion and Monetization May 9, 2022
  • Tweets at #WMIF2022 by @pharma_BI & @AVIVA1950 and all Retweets of these Tweets – 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON May 7, 2022
  • Data Science: Step by Step – A Resource for LPBI Group’s One-Year Internship in IT, IS, DS May 7, 2022
  • 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON • IN-PERSON May 1, 2022
  • We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022 April 25, 2022
  • The durability of T cells versus the triggered of high levels of antibodies: Rationale for the development of T cells focused vaccines   April 22, 2022
  • The Framingham Study: Across 6 Decades, Cardiovascular Disease Among Middle-Aged Adults – mean life expectancy increased and the RLR of ASCVD decreased. Effective primary prevention efforts and better screening increased. April 22, 2022

• Archives

  Archives Select Month May 2022  (7) April 2022  (10) March 2022  (7) February 2022  (7) January 2022  (3) December 2021  (3) November 2021  (4) October 2021  (11) September 2021  (5) August 2021  (8) July 2021  (21) June 2021  (8) May 2021  (10) April 2021  (8) March 2021  (15) February 2021  (17) January 2021  (20) December 2020  (10) November 2020  (12) October 2020  (26) September 2020  (17) August 2020  (22) July 2020  (27) June 2020  (33) May 2020  (26) April 2020  (42) March 2020  (22) February 2020  (11) January 2020  (7) December 2019  (20) November 2019  (13) October 2019  (11) September 2019  (3) August 2019  (8) July 2019  (25) June 2019  (47) May 2019  (40) April 2019  (27) March 2019  (29) February 2019  (17) January 2019  (50) December 2018  (14) November 2018  (17) October 2018  (18) September 2018  (17) August 2018  (8) July 2018  (20) June 2018  (22) May 2018  (17) April 2018  (12) March 2018  (20) February 2018  (26) January 2018  (16) December 2017  (6) November 2017  (20) October 2017  (13) September 2017  (16) August 2017  (16) July 2017  (19) June 2017  (20) May 2017  (32) April 2017  (21) March 2017  (10) February 2017  (24) January 2017  (21) December 2016  (43) November 2016  (8) October 2016  (40) September 2016  (67) August 2016  (59) July 2016  (75) June 2016  (37) May 2016  (95) April 2016  (152) March 2016  (175) February 2016  (196) January 2016  (139) December 2015  (90) November 2015  (287) October 2015  (237) September 2015  (115) August 2015  (96) July 2015  (63) June 2015  (44) May 2015  (53) April 2015  (76) March 2015  (95) February 2015  (83) January 2015  (75) December 2014  (75) November 2014  (88) October 2014  (135) September 2014  (117) August 2014  (88) July 2014  (88) June 2014  (109) May 2014  (60) April 2014  (85) March 2014  (58) February 2014  (72) January 2014  (107) December 2013  (104) November 2013  (136) October 2013  (62) September 2013  (32) August 2013  (46) July 2013  (74) June 2013  (110) May 2013  (112) April 2013  (86) March 2013  (92) February 2013  (63) January 2013  (63) December 2012  (46) November 2012  (71) October 2012  (84) September 2012  (82) August 2012  (122) July 2012  (59) June 2012  (34) May 2012  (46) April 2012  (2)

• Categories

  Categories Select Category 3D Printing for Medical Application  (153)    3D Plotting Scaffolds  (43)    BioInks  (19)       Biopolymer Blend Open Porous  (17)       Dental Applications  (10)    BioPrinting in Regenerative Medicine  (35)       Cell Level  (10)       MicroEngineering Cell-Tissue & Systems  (24)       Tissue Engineering  (32)    Cardiovascular and Vascular Systems  (17)       Artificial Vascular Structures  (8)       Cardiovascular Tissue  (7)    Drug Development using MultiOrgan Chip  (11)    Drug Development/Formulation using 3D Printing  (8)    MEMS  (10)       Bio-MEMS  (10)    Organ-on-a-Chip  (9)    Programmable Sensors (Carbon Nano Tubes)  (5) 3rd Party IP: Drug DIscovery  (1) 4D Printing and Meta Materials  (9) Academic Publishing  (214)    Key Opinion Leaders in eScientific Publishing – Interviews with  (7) Advanced Drug Manufacturing Technology  (72)    Antimalarial Preparation  (8)    Autologous Cell Therapy  (11)    Automated Cell Processing  (11) Allergy and Infectious Diseases  (12) Alzheimer’s Disease  (130)    Etiology  (76)    Medical Device Therapies for Altzheimer’s Disease  (13)    Pharmacotherapy and Cell Activity  (48) Anticancer Resistance  (28) Aortic Valve: TAVR  (4) Art Exhibits on the Human Condition  (1) Art Inspires Science  (3) Artificial Heart  (2) Artificial Intelligence – General  (91)    An executive’s guide to AI  (9)    Artificial Intelligence – Breakthroughs in Theories and Technologies  (73)    Artificial Intelligence Applications in Health Care  (68)       Artificial Intelligence in CANCER  (23)       Artificial Intelligence in Health Care – Tools & Innovations  (47)    Artificial Intelligence in Medicine – Application for Diagnosis  (39)       Artificial intelligence applications for cardiology  (20)          AI-assisted Cardiac MRI  (9)       Artificial Intelligence in Psychiatry  (5)       Deep Learning in Pathology  (12)    Artificial Intelligence in Medicine – Applications in Therapeutics  (39)    Machine Learning  (21)       Natural Language Processing (NLP)  (10)    Machine learning in predicting type 2 diabetes  (1) Auditory and vision  (12) Autism Spectrum Disorders  (10) Autoimmune Inflammatory DIseases  (17)    Crohn’s disease  (5)    Tolerance-inducing Autoimmune Disease Therapeutics  (2)    Ulcerative Colitis  (3) Autophagosome  (2) Bacterial Resistance  (24) Behavior  (22) Behavioral Genetics  (19) Big Data  (63)    Intelligent Information Systems  (43) Bio Instrumentation in Experimental Life Sciences Research  (355)    Analytical Instruments Industry  (3)    Microfuidics  (6) Bio-Ethics  (13) BioBanking  (32) Biodegradable Drug-eluting Material  (7) Bioengineering & reverse engineering design  (40) BioIT: BioInformatics  (130) BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics  (97)    Advanced Computing Platform  (14)       Blockchain Transactions System  (5)          Platform for Content Monetization embedded Content Promotion  (1)    Pancreatic adenocarcinoma classifier  (3)    Simulation Modeling in NGS  (2) Biological Engineering  (36) Biological Networks  (182) Biological Networks, Gene Regulation and Evolution  (460)    Virology  (9) Biomarkers & Medical Diagnostics  (559)    VOC – Volatile Organic Compounds as BioMarkers  (1) Biomedical Measurement Science  (170) BioSimilars  (108) BioTechnology – Venture Creation  (119)    Foundations for supporting Science and Education  (12)    Philanthropy to Academic Institution  (2) BioTechnology – Venture Creation, Venture Capital  (103)    Seeking Talent  (3) BiVAD  (1) Blindness  (6) Bone Disease and Musculoskeletal Disease  (79) Brain Basis of Emotion  (4) Business Career Consideration  (1) Ca2+ triggered activation  (58) Calcium  (18) Calcium Signaling  (66) Calmodulin Kinase and Contraction  (33) Cancer – General  (170) Cancer and Current Therapeutics  (382)    interventional oncology  (26)       Breast Cancer – impalpable breast lesions  (17)       Prostate Cancer: Monitoring vs Treatment  (8) CANCER BIOLOGY & Innovations in Cancer Therapy  (998)    Anaerobic Glycolysis  (51)    Cachexia  (18)    Cancer Genomics  (54)       Circulating Tumor Cells (CTC)  (13)          Liquid Biopsy Chip detects an array of metastatic cancer cell markers in blood  (8)             mRNA  (5)          MagSifter chip  (1)       KRAS Mutation  (5)       Li-fraumeni syndrome.  (2)       TP53 – Germline mutations  (4)    cancer metabolism  (18)    Funding Opportunities for Cancer Research  (10)    Genomic Expression  (140)    Glioblastoma  (7)    Hexokinase  (14)    Loss of function gene  (17)    Metabolic Immuno-Oncology  (13)    Metastasis Process  (9)    Methylation  (30)    Microbiome and Responses to Cancer Therapy  (5)    Monoclonal Immunotherapy  (27)    mtDNA  (13)    Oxidative phosphorylation  (56)    Pancreatic cancer  (9)    Pyruvate Kinase  (27)    The NCI Formulary  (1)    tumor microenvironment  (13)    Warburg effect  (50) Cancer Informatics  (92) Cancer Prevention: Research & Programs  (125) Cancer Screening  (101) Cancer Vaccines: Targeting Cancer Genes for Immunotherapy  (24)    Engineering Enhanced Cancer Vaccines  (3) cancer-general  (1) Cardiac and Cardiovascular Surgical Procedures  (199)    Aortic Valve: TAVR, TAVI vs Open Heart Surgery  (82)       Prosthesis-Patient Mismatch (PPM) in TAVI vs SAVR  (1)       TAVI vs Open Heart Surgery  (4)       Transcaval TAVR Procedure  (2)       Valve-in-Valve Procedure  (3)    Atrial Fibrilation (a-Fib), Cardiac Pacing and Arrhythmias  (13)    BackBeat’s Cardiac Neuromodulation Therapy (CNT) bioelectronic therapy  (1)    CABG  (44)    Cancer Surgery of the Heart  (10)    Cardiovascular Fluid Management: algorithms  (1)    Heart Transplant  (14)    Heart-Lung Transplant  (9)    Implantation  (2)    Left Main Coronary Artery Disease (LMCAD)  (3)    Mechanical Assist Devices: LVAD, RVAD, BiVAD, Artificial Heart  (19)    Mitral Valve: Repair and Replacement  (60)       TMVR – Transcatheter Mitral Valve Repair  (3)    PCI  (92)       Bioresorbable Vascular Scaffold (BVS)  (3)       Robotic-assisted percutaneous coronary intervention  (1)       Stent Retriever in endovascular thrombectomy  (1)    Peripheral Arterial Disease & Peripheral Vascular Surgery  (45)       Abdominal Aorta  (19)       Carotid Artery  (15)       Thoracic Aorta  (15)    Pulmonary Valve Replacement and Repair  (2)    Renal Denervation  (20)    Replacement  (1)    Tricuspid Valve Repair  (6)    Vena Caval Filters: Device for Prevention of Pulmonary Embolism and Thrombosis  (1) Cardiovascular Pharmacogenomics  (168) Cargo  (3) Cell Biology  (312) Cell Biology, Signaling & Cell Circuits  (637)    Apoptosis  (14)    Autophagy-Modulating Proteins  (5)    “Antibody–enzyme conjugates”  (4)    Cell Processing System in Cell Therapy Process Development  (20)    Endoplasmic reticulum  (2)    Enzymatic mechanism underlying the synthesis of adenosine triphosphate (ATP)  (1)    Ubiquitin  (6) Cerebrovascular and Neurodegenerative Diseases  (114)    Stroke  (4) Chemical Biology and its relations to Metabolic Disease  (452)    #BIGAxisSummit  (1)    Gut Microbiome and Obesity  (7) Chemical Genetics  (347) Child and Adolescent Psychiatry  (13) Childhood cancer  (13) Childhood malnutrition  (3) children  (1) Circulating Progenitor Cells  (14)    Bone marrow derived cells  (17)    Endothelial cells  (7)    Umbilical cord cells  (6) Clinical & Translational  (233) Clinical Diagnostics  (213)    Mass automation of plasma proteins  (13) Clinical Genomics  (134) Coagulation Therapy and Internal Bleeding  (80) Cognition  (43) Commercialization  (20) Components and IRB related issues  (4) Computational Biology/Systems and Bioinformatics  (459)    Computational Histopathology  (1)    Meta-analysis of transcriptome data  (8) Conference Coverage with Social Media  (464)    MassBio  (3) coronavirus  (16) COVID-19  (20) CRISPR/Cas9 & Gene Editing  (179)    CRISPR alternative for editing genes without cutting  (11)       CAST – Alternative to CRISPR/Cas9  (3)       Transposon-encoded CRISPR–Cas systems direct RNA-guided DNA integration  (4)    CRISPR applied to Human Germ Line  (9)       Gene Editing Impact on Longevity  (4) CT  (19) Cytokines  (19) Cytoskeleton  (84) Developmental biology  (104) Diabetes Mellitus  (137)    Artificial Pancreas for Type 2 Diabetes  (1)    Artificial Pancreas for Type1 Diabetes  (5)    Gestational diabetes  (2) Diagnostic Immunology  (54) Diagnostics and Lab Tests  (116)    Liquid Biopsy: Circulating Tumor Cells in Urine and Blood  (8) Digital HealthCare – biotech & internet joint ventures  (37) Disease Biology  (324) Disease Biology, Small Molecules in Development of Therapeutic Drugs  (481) DNA repair  (43)    Apoptosis  (11)    Autophagy  (12)    Cell death pathways  (18)    Proteolysis  (8)    Proteosome  (7) Drug Delivery Platform Technology  (141)    Drug Carrier Design  (13)       Medication Remote Compliance Monitoring  (3)    Exosomes: Natural Carriers for siRNA Delivery  (9) Drug Toxicity  (74) Ecosystems & Industrial Concentration in the Medical Device Sector  (95)    Cardiac & Vascular Repair Tools Subsegment  (128)    Exec Compensation in the Cardiac & Vascular Repair Tools Subsegment  (14)    Massachusetts Niche Suppliers and National Leaders  (20) Electronic Health Record  (8) Embryology  (24) Empathy  (6) Endocrine Diseases  (58) Enzyme Induction  (42)    ion-transporting enzyme  (1)    K + -ATPase.  (1)    Na +  (1) Epigenetics and Environmental Factors  (23) Ethics and Leadership  (10) Executive Compensation – Big Pharma  (3) Fat soluble vitamins  (4) FDA  (67) FDA Regulatory Affairs  (328)    FDA, CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP, GLP, ISO 14155  (50)    ISO 10993 for Product Registration: FDA & CE Mark for Development of Medical Devices and Diagnostics  (30) Fetal Ultrasound  (2) Fiction and medicine  (4) Frontiers in Cardiology and Cardiovascular Disorders  (609)    Acute Myocardial Infarction  (46)       Cardiogenic Shock  (3)    Anemia in CVD Patients  (6)    Cardio-Oncology  (4)    Cardiomyopathy  (54)    Cardiovascular Research  (143)       Myocardial metabolism, Myocardial ischemia, Myocardial adenine nucleotide metabolism  (43)       Pre-Clinical Animal Model Development  (23)    Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Pulmonary Arterial Hypertension (PAH)  (19)    Cost of Inpatient Stay for Cardiovascular Diagnosis for Admission  (1)    Electrophysiology  (94)       Ablation Procedure vs Drug Therapy  (1)       Arrhythmia Detection with Machine Learning Algorithms  (5)       Cardiotoxic Risks of Immune Checkpoint Inhibitors  (1)       Genomic Analysis of EKG Electrophysiology Genomics  (2)       implantable cardioverter defibrillator (ICD) and External Defibrillation  (1)       implantable pacemaker  (2)       Rare heart rhythm disorders and Long QT syndrome (LQTS)  (5)    Epigenetics and Cardiovascular Risks  (55)    Heart Failure (HF)  (28)       Acute coronary syndrome  (5)       congestive heart failure  (17)       Hypertensive Disorders of Pregnancy  (0)    Medical Devices R&D and Inventions  (156)       Assist Devices: LV  (3)       RV  (1)       Stents & Tools  (87)       Valves & Tools  (64)    Origins of Cardiovascular Disease  (375)       Atherogenic Processes & Pathology  (167)       Congenital Heart Disease  (32)          Genetic Mutations in Congenital Heart Disease  (4)       inflammation independent of lipid levels  (11)       Systemic Inflammatory Diseases as CVD Risk  (10)    Pharmacotherapy of Cardiovascular Disease  (247)       HTN  (156)       HTN in Youth  (7)       Resident-cell-based  (42)       Subarachnoid Hemorrhage (SAH)  (1)       Transthyretin amyloid cardiomyopathy (ATTR-CM)  (1)    Spontaneous Coronary Artery Dissection (SCAD)  (6)    Stroke  (6)       endovascular thrombectomy  (2)    Vascular Diseases  (12) Future Pandemics Inform-graphics  (1) Gastroenterology  (37) Gene Regulation  (224) Gene Regulation and Evolution  (132) Genetics & Innovations in Treatment  (168) Genetics & Pharmaceutical  (197) Genome Biology  (907)    Exosomes  (23)    Gene Therapy & Gene Editing Development  (37)    mRNA Therapeutics  (17)    Mutagenesis  (26)    Single Cell Genomics  (21)    Single-cell sequencing  (16)    Variation in human protein-coding regions  (25) Genomic Endocrinology  (40) Genomic Testing: Methodology for Diagnosis  (410) Genomics Pharmacy  (36) Global Market of Medical Devices Technology  (1) Global Medical Publishers by Country  (2) Global Partnering & Biotech Investment  (43) GLP  (4) Glycobiology: Biopharmaceutical Production  (12) Glycobiology: Biopharmaceutical Production, Pharmacodynamics and Pharmacokinetics  (25) Health Care System by Country  (31)    AI Models in Healthcare  (5)    Centers for Medicare & Medicaid Services  (7)    Health in Israel  (2)    India  (0)    United States  (17)       Hospital-based Medical Innovations  (7)       Medical Recertification and Maintenance of Certification (MOC)  (1) Health Economics and Outcomes Research  (369)    Women Health  (9)       Heart and Brain Disease in Women  (3) Health Law & Patient Safety  (148)    and Bioethics  (13)    Biotechnology  (10)    Health Law Policy  (10) HealthCare IT  (131) Healthcare Reform  (62)    Accountable Care Organizations  (25)    Affordable Care Act  (28)       Repair  (1)       Repeal ACA  (1)       Replace  (1)    Federal Budget Appropriations  (25)    Healthcare costs and reimbursement  (54)    Indigent Nutrition  (13)    Medicare and Medicaid  (20)    Prescription Drugs Costs  (20)    Skilled Nursing Facilities  (6)    Technology Capital Expenses  (15)    Uninsured and Underinsured  (19) Hematology  (74)    Acute lymphocytic leukemia  (18)    Acute myelocytic leukemia  (21)    Hematopoiesis  (48)    Lymphoma  (21) History and physical exam  (6) Human aging  (27) Human Immune System in Health and in Disease  (234) Human Sensation and Cellular Transduction: Physiology and Therapeutics  (20) Image Processing/Computing  (41) Imaging-based Cancer Patient Management  (116) Immuno-Oncology & Genomics  (121)    mRNA platform in Drug DIscovery  (6) Immunodiagnostics  (108)    Cancer-Immune Interactions  (19)    CNS-Immune Interface  (3)    Neuronal Circuits  (4) Immunology  (94)    Adaptive Immune Response to Biomaterials and Tissue Repair  (8)    Antibody Responses Predict Antigen Exposure  (10)    Cytokine Receptor Structure  (7)    Human Antibody Response  (15)    Human Circulating Antibody Repertoire  (9)    Human Naive B Cell Repertoire  (8)    MHC Repertoires for Antigen Prediction  (8)    Protection Against Autoimmune Disease  (7)    Synthetic Immunology: Hacking Immune Cells  (12) Immunotherapy  (100)    CAR-T  (13)    combination immunotherapies.  (11)    Efficacy of Anti-Tumor T Cells  (11)    Engineering Better T Cells  (7)    Immune Engineering  (13)    Immune Modulatory  (13)    Integrin-targeted Combination Immunotherapy  (5)    Modulating Macrophages in Cancer Immunotherapy  (11)    NK Cell-Based Cancer Immunotherapy  (16)    Synergistic Innate and Adaptive Immunotherapy  (12) Income Disparity  (2) Infectious Disease & New Antibiotic Targets  (136)    Antibiotic resistance  (5)    Viral diseases  (32)       Myocarditis  (1) Infectious Disease Immunodiagnostics  (44)    Virology – Vector-borne DIsease  (14) Inflammasome  (25)    Anti-tumor necrosis factor drugs (TNF inhibitors)  (2) Innovation in Immunology Diagnostics  (101)    Universal Immune Cell Therapies (uICT)  (8) Innovations  (177)    R&D Expenditure  (2) Innovations in Neurophysiology & Neuropsychology  (130)    Age and Life Expectancy  (1)    autism spectrum disorder  (1)    Circadian Rhythm and Sleep  (6)    hNPCs  (1)    Nervous System Function  (1)    Relapsing Multiple Sclerosis  (1) Intellectual Property  (72)    Disputes and Settlements  (8)    IP Valuation Models – Pricing Intangible Assets  (4)    Patent Law in Biotech  (12) Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough  (104) International Global Work in Pharmaceutical  (187) Interventional Oncology: Radiofrequency Ablation, Transarterial Chemoembolization, Microwave Ablation and Irreversible Electroporation (IRE)  (12) Interviews with Scientific Leaders  (274)    Albany Medical Center Prize in Medicine and Biomedical Research  (1)    Annual Breakthrough Prize  (2)    Annual Lewis S. Rosenstiel Award  (1)    Awards in Cardiology and Cardiovascular Medicine  (3)    CEOs of Biotech Companies  (2)    Gerald D Aurbach Award for Outstanding Translational Research  (1)    Interviews with Key Opinion Leaders (KOLs)  (6)    James Prize in Science and Technology Integration  (1)    Jessie Stevenson Kovalenko Medal – Medical Sciences  (1)    Lemelson-MIT Prize  (1)    Life Sciences Breakthrough Prize  (2)    Mosteller Statistician of the Year Award  (1)    Mourning the Loss of a Scientific Leader  (2)    National Academy of Sciences AWARDS  (2)    Nobel Prize WInners  (17)    Noble Prize (Not Nobel Prize)  (1)    Paul Marks Prize for Cancer Research  (1)    Russ Prize recognizes bioengineering achievements worldwide  (1)    The Dan David Prize  (5)    Warren Alpert Foundation Prize Recipients  (3)    Wolf Prize  (1)    Wolf Prize in Medicine  (1)    women in science  (3) Investment in Technological Breakthrough  (58) Ionic Transporters Na+  (25) IP Development by LPBI Group Team  (9) IP Development by LPBI Group Team & Other Organizations  (7) ISO 14155  (3) Joint Venture – SBH & M3DP: SOP and Arrangements  (1) Justice & Law  (1) K  (15) Lab-on-a-chip  (2) Landscape  (1) Lasers and photonics  (18)    Midrange IR spectroscopy  (1) Law and Medicine Conflicts  (13) Leadership, Power, Social Interlocking Connections  (13) Lipid metabolism  (93)    Fatty acids  (37)    Lipids  (37)    PCSK9 Inhibitor Therapy  (19) Lipidomics  (10) Liposome  (3) Liver & Digestive Diseases Research  (118) LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management  (109)    Award Nominations  (5)    BioMed e-Books e-Series by LPBI Group  (6)    Feedback from Investors: LPBI Portfolio of Five Businesses  (2)    LPBI Group Founder – Aviva Lev-Ari  (21)    PhD  (1)    RN  (1) LPBI Management  (13) Massachusetts Academy of Sciences (MAS)    (2) Materials Science & Engineering  (31) Math  (10)    Great Discoveries  (7) Mechanical Assist Devices: LVAD  (4) Medical and Population Genetics  (190) Medical Devices R&D Investment  (222)    21st Century Cures Act  (2)    CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP  (13)    Rhythm management device hardware: dual-chamber pacemakers  (1)       Systolic HTN  (1) Medical Imaging Technology  (52) Medical Imaging Technology, Image Processing/Computing, MRI, CT, Nuclear Medicine, Ultra Sound  (143)    Circumferential-Intravascular-Radioluminescence-Photoacoustic-Imaging (CIRPI)  (2)    Echocardiography  (1)    Invasive FFR for PCI  (2)    MRI  (15)    Noninvasive Diagnostic Fractional Flow Reserve (FFR) CT  (4)    Ultra Sound  (7) Melatonin & Circadian Regulation  (7) memory loss  (1) Metabolism  (206)    Biochemical pathways  (126)       Enzymes and isoenzymes  (56)          Dehydrogenase  (15)          Kinase  (27)          Phosphatase  (8)          Phosphorylase  (21)          tyrosine decarboxylases  (2)    Inosine nucleotides  (8)    Leloir pathway  (6)    microbiome  (6)    Pentose monophosphate shunt  (14)    Pyridine nucleotides  (28)       Pyridine nucleotide transhydrogenase  (7) Metabolomics  (316) Methods  (37) Mg++  (10) Microbiologial genetics  (31) Microbiology  (51)    Virology  (12) Micronutrients  (15) Microvesicle  (6) Microwave Ablation and Irreversible Electroporation (IRE)  (1) Mobile Healthcare  (3) Molecular Genetics & Pharmaceutical  (372)    Organoids  (3) Monoclonal antibody therapy  (9) Mutant Gene Expression  (41) Myocardial adenine nucleotide metabolism  (5) Myocardial Ischemia  (24) Myocardial Metabolism  (34) Na-K transport  (39) Na-K-ATPase  (26) Nanotechnology for Drug Delivery  (90) Nephrology  (45) Nephrology & Regenerative medicine  (8) Neurodegenerative Diseases  (82)    hNPCs  (3)    MS  (4) Neurohumoral Transmission  (52)    Ca2+ triggered activation  (19)    Calmodulin  (12)    Parkinson’s disease dyskinesia levodopa  (2)    PKC  (13)    Synaptic vesicle  (20) Neurological Diseases  (119) Neuroscience  (121) Next Generation Sequencing (NGS)  (21)    Nanopore sequencing  (1) NIH Common Fund  (1) Nitric Oxide in Health and Disease  (135) Nuclear Medicine  (11) Nutrigenomics  (67) Nutrition  (186)    Nutritional Supplements: Atherogenesis, lipid metabolism  (47) Nutrition and Phytochemistry  (57)    Minerals in Medicine  (4)    Plant extract  (21) Nutrition Disorders  (29) Nutritional Supplements: Atherogenesis  (30) Obesity  (17) Oligonucleotide Therapeutics & Delivery  (6) Oncolytic virus & OncoViro-Therapy  (19)    Synthetic Virology  (1) Organ-on-a-Chip & 3D Printing in Life Sciences  (7) Pain: Etiology, Genetics & Innovations in Treatment  (23) Parasitology  (3)    Malaria  (4)    Tropical diseases  (1) Patents  (34) Patient Experience  (52)    Art therapy  (1)    Hospital reputation  (7)    Humor  (1)    Music therapy  (2)    Pain Alleviation  (7)    Patient Outlook  (28)    Reputation of Interventionist  (4)    Support Staff  (13)    Supportive therapies  (6)       laughfter  (1)    Surgical Procedure  (7) Patient Experience: Personal Memories of Invasive Medical Intervantion  (30) Patient’s Voice: Personal Experience with Invasive Medical Procedures  (18) Perioperative Statins at Noncardiac Surgery  (1) Personal Health Applications: Tech Innovations serves HealhCare  (34) Personalized and Precision Medicine & Genomic Research  (680)    Longevity  (1)    New Drug Approval  (3)    Patient-centered Medicine  (24)       cell-based therapy  (7)       stem cell biology and patient-specific  (6)    Personalized Medicine Coalition  (8)    Precision Cancer Medicine  (16) Phagophore  (1) Pharmaceutical Analytics  (245)    Pharmacologic toxicities  (61) Pharmaceutical Discovery  (97)    Rapid automation of plasma protein pools  (16) Pharmaceutical Drug Discovery  (164)    Drug Development Process  (39)       Drug Discovery Chemistry  (21)    drug repurposing  (7) Pharmaceutical Industry Competitive Intelligence  (329)    Pharmacovigilance  (6)    Value-based Drug Pricing  (8) Pharmaceutical R&D Informatics  (41) Pharmaceutical R&D Investment  (297) Pharmacodynamics and Pharmacokinetics  (22) Pharmacogenomics  (155) Photography Collection  (1) Physics  (12) Placenta  (6) Population genetics  (25) Population Health Management  (180)    Evolution of Biology Through Culture  (12)    U.S. Employment-to-Population Ratio  (8) Population Health Management, Genetics & Pharmaceutical  (563)    COVID-19  (140)       Biomarkers: Inflammation  (36)       Cancer Researchers Fighting COVID-19  (14)       COVID-19 effects on Human Heart  (15)       COVID-19: Pandemic Surgery Guidance  (19)       Economic Impact of Coronavirus Pandemic  (41)       number of asymptomatic infections  (27)       Treatment Protocols for COVID-19  (62)    SARS-CoV-2  (130)       Coronavirus Gene Expression  (58)          SARS-CoV-2 circulating variants   (14)          SARS-CoV-2 Viral Variants  (18)       Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis  (2)       Immune-Mediation (independent immunopathology: lung and reticuloendothelial system)  (29)       Mechanisms of infection by SARS-CoV-2  (21)       SAR-Cov-2 a vasculotropic (blood vessels) RNA Virus  (31)          SARS-COV2 Hijacking the Complement and Coagulation Systems  (19)       Seasonality & Environmental Factors in Resurgence  (26)       Serology tests for coronavirus antibodies  (44)       T-cell response to SARS-CoV-2 infection  (14)       Vaccinology  (51)          Mechanism of Thrombosis with AZ & J&J COVID-19 Vaccines  (5)       Virtual Drug Molecule Screening targeting SAR-CoV-2 proteins  (8)    Virus Infective Acute Respiratory Syndrome: SARS-CoV  (92) Population Health Management, Nutrition and Phytochemistry  (150) Preimplantation Genetic Diagnosis and Reproductive Genomics  (11) Protein-energy malnutrition  (11) Proteomics  (340)    Amino acids  (50)    Proteins  (131) Pulmonary diseases  (4)    Lung and pulmonology  (13) Pulmonary pathology  (6) Radio Frequency (RF)-based Surgical Solutions  (2) REAL TIME Conference Coverage Twitter’s Hashtags and Handles per Presentation/session  (29) Regenerative Biology and Medicine  (84) Regulated Clinical Trials: Design, Methods, Components and IRB related issues  (265) Reproductive Andrology, Embryology, Genomic Endocrinology, Preimplantation Genetic Diagnosis and Reproductive Genomics  (105) Reproductive Biology & Bio Instrumentation  (71) RNA Biology  (73)    RNA interference (RNAi) therapeutic  (4) RNA Biology, Cancer and Therapeutics  (59) RVAD  (1) SBIR, SBA, NIH, NSF  (2) Schizophrenia  (14) Scientific & Biotech Conferences: Press Coverage  (172) Scientific Publishing  (31)    Curation  (559)       Curation methodology  (38)       De novo synthesis  (16)       Dialectic  (17)       Discovery process  (70)       Evolutionary cognition  (53)       Experimental validation  (90)       Explanatory  (92)       Historical relevance  (72)       Technology Advance Assessment of  (69)       Theoretic convergence  (27)    Open Access Journals  (34) Scientist: Career considerations  (183)    Big Data & Analytics  (13)    Data Science  (10)    Women in Life Sciences  (10) Scoop.it  (18) Sensors & Analytics  (16) Sepsis  (2) Severe Autism  (3) Signaling  (89)    Phosphorylation  (40)    S-nitrosylation  (11)    Ubiquitinylation  (31) Signaling & Cell Circuits  (125) single cell sequencing  (1) Small Molecules in Development of Therapeutic Drugs  (67) Social Development  (15) Specialized 3D BioPrinters (Cornea  (1) Statistical Methods for Research Evaluation  (136) Stem Cells for Regenerative Medicine  (164)    Cardiac muscle regeneration  (17)    Competition in regenerative stem cell science  (17)    Human neural progenitor sells  (6)    Skeletal muscle regeneration  (8) STORM  (2) Stress Disorders  (18) Substance Abuse  (4) Systemic Inflammatory Response Related Disorders  (155)    Inflammatory Pathophysiology  (4) Technology Transfer: Biotech and Pharmaceutical  (351) therapeutics  (1) Tissue Engineering and Regenerative Medicine  (21) Tissue Microenvironment  (3) Transarterial Chemoembolization  (2) Transcriptomics  (42) Transformative Technologies in Healthcare  (11) Translational Science  (186)    Best evidence  (52)    Bias measurement tools  (2)    Evidence-based decision-making  (26)    Inferential analysis  (25)    Intra-rater error  (1)    Quality Assurance  (8)    Random Error  (2)    Systematic Error (Bias)  (5)    Total error  (2)    Translational Effectiveness  (49)    Translational Research  (86) Trends in Global Economy  (4) Uncategorized  (1,332) Unfolded Protein Response (UPR)  (5) US and Global Economy: Trends and Findings  (7) Venture Capital  (42)    Income Geographic Distribution  (2)    Institutional Capital Raised by Female Founders  (4) virology  (6) Vision  (6) Voices of Patients and Healthcare Providers  (21) Water Transporters  (7) Wearable Tech + Digital Health  (3) Anemia  (13) Neutropenia  (8) Neutrophilia  (9) Platelet count disorder  (9) Folate and B12  (7) Iron deficiency  (5) Myelodysplasia  (12) Myelofibrosis  (10)

• Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

• • 2012pharmaceutical
  • Amandeep Kaur
  • Aashir Awan, Phd
  • Abhisar Anand
  • Adina Hazan
  • Alan F. Kaul, PharmD., MS, MBA, FCCP
  • alexcrystal6
  • anamikasarkar
  • apreconasia
  • aviralvatsa
  • David Orchard-Webb, PhD
  • danutdaagmailcom
  • Demet Sag, Ph.D., CRA, GCP
  • Dror Nir
  • dsmolyar
  • Ethan Coomber
  • evelinacohn
  • Gail S Thornton
  • Irina Robu
  • jayzmit48
  • jdpmd
  • jshertok
  • kellyperlman
  • Ed Kislauskis
  • larryhbern
  • Madison Davis
  • marzankhan
  • megbaker58
  • ofermar2020
  • Dr. Pati
  • pkandala
  • Rosalind Codrington, PhD
  • ritusaxena
  • Rick Mandahl
  • sjwilliamspa
  • Srinivas Sriram
  • stuartlpbi
  • Dr. Sudipta Saha
  • tildabarliya
  • vaishnavee24
  • zraviv06
  • zs22